Alpha Tau enters strategic marketing alliance with Oramed

Alpha Tau Medical (DRTS) closed a registered direct offering whereby an affiliate of Oramed Pharmaceuticals (ORMP) purchased 14,110,121 of Alpha Tau’s ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. The offering closed on April 28, 2025. The total gross proceeds of the offering were approximately $36.9M, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau intends to use the net proceeds from the offering for general corporate purposes, including research and development-related purposes in connection with its product candidates, for expansion of its manufacturing capabilities and for potential commercialization of its product candidates. In addition, the parties have entered into an agreement whereby an affiliate of Oramed will provide Alpha Tau with certain strategic services over the next three years in exchange for payments from Alpha Tau as well warrants to purchase additional Alpha Tau shares.